

US Antidiabetics Drug Market Outlook 2022

<https://marketpublishers.com/r/U0B1E440CAFEN.html>

Date: March 2017

Pages: 120

Price: US\$ 1,800.00 (Single User License)

ID: U0B1E440CAFEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“US Antidiabetics Drug Market Outlook 2022” report gives clinical and non-clinical insight on trends associated with the development of Antidiabetics drug market in US. Report helps to identify the diabetes epidemiology (Prevalence of Type 1 & 2 Diabetes) in the US market along with the associated economic burden and productivity loss.

Diabetes rates in the US have been increasing substantially. While the number of people with diabetes in the US continues to grow, the number of new cases has been declining since 2009, after decades of increases in new cases. Although the numbers are not growing dramatically each year, they are still alarmingly high. About 8.1 Million people with diabetes do not have knowledge that they have diabetes as prediabetes and type2 diabetes have few physical symptoms.

Diabetes mellitus being the most common chronic disease with high mortality, morbidity and costs, the number of people with diabetes is still increasing in US and other countries. More than 29 million Americans are living with diabetes, and 86 million are living with prediabetes. Though the benefits of tight control of blood glucose have been well recognized still the management of diabetes is complex which demands for the more efficient standardized antidiabetic regimen.

US insulin market occupies more than 70% of the overall insulin market and is expected to grow significantly until 2022 owing to the growing number of individuals with diabetes. Factors such as better accessibility to treatment therapies and favorable reimbursement programs will result in the high turnout of patients opting for diabetes treatment, which in turn will boost the market’s growth prospects in this region.

The US Antidiabetics Drug Market has seen a resurgence of activity in recent years with

promising new products, such as ultra-rapid-acting and liver targeted insulin analogues, and insulin plus GLP-1 combinations in late stage development. Earlier stage candidates include several oral formulations, as well as ultra-long acting insulin analogues. Some ultra-long acting insulin analogues in development have the potential to greatly reduce the dosing frequency to just once weekly for basal insulin needs, as opposed to once daily.

In addition, the prospect of promising drugs in the pipeline, along with increasing awareness, is expected to contribute to the market's growth during the forecast period. The market is dominated by three key players: Eli Lilly, Novo Nordisk, and Sanofi. Novo Nordisk is the major vendor in the global insulin market. The largest product wise market revenue was generated by Lantus, which is marketed by Sanofi.

“US Antidiabetics Drug Market Outlook 2022” report highlights:

US Diabetes Epidemiology

US Antidiabetics Market Overview

Key Marketed Antidiabetic Drugs in US

US Biosimilar Insulin Market

US Antidiabetics Drug Market Future Prospects

Contents

1. ANTIDIABETICS: REGIMEN FOR DIABETES MELLITUS

- 1.1 Prologue Towards Diabetes
- 1.2 Preface to Antidiabetics

2. ANTIQUITY OF MANAGING DIABETES MELLITUS

- 2.1 Trajectory from Diabetes to Insulin
- 2.2 Historical En Route towards Oral Diabetic Medication

3. TREATMENTS AVAILABLE FOR DIABETES MELLITUS

- 3.1 Non-Pharmacological Approaches for Diabetes Mellitus
- 3.2 Pharmacological Approaches for Diabetes Mellitus

4. CATALOGUING OF ANTIDIABETIC AGENTS

- 4.1 Antidiabetic: Oral Agents
 - 4.1.1 Biguanides
 - 4.1.2 Thiazolidinediones (TZDs)
 - 4.1.3 Sulfonylureas
 - 4.1.4 Meglitinides
 - 4.1.5 α -Glucosidase Inhibitors
 - 4.1.6 Dipeptidyl Peptidase-4 Inhibitor
 - 4.1.7 Bile Acid Sequestrants (BAS)
 - 4.1.8 Dopamine Agonist-2

5. ANTIDIABETIC: INJECTABLE DRUGS

- 5.1 Insulin: A life saving Modality
- 5.2 Non-Insulin Alternatives for Diabetes Mellitus

6. US DIABETES EPIDEMIOLOGY

- 6.1 Prevalence of Type 1 & 2 Diabetes
- 6.2 Economic Burden Associated with Type 1 & 2 Diabetes: Productivity Loss & Medical Bills

7. US ANTIDIABETICS MARKET OVERVIEW

- 7.1 Antidiabetic Injectable Market Trends in US
- 7.2 Antidiabetic Oral Drugs Market Trends in US
- 7.3 Commending Trends of Antidiabetics

8. US: KEY MARKETED ANTIDIABETIC DRUGS

- 8.1 Insulin Degludec (Tresiba)- Injection
- 8.2 Insulin Lispro - Injection
- 8.3 Insulin Inhalation(Afrezza) - Inhalation
- 8.4 Insulin Glargine (Toujeo) - Injection
- 8.5 Insulin Glulisine (Apidra) - Injection
- 8.6 Insulin Aspart (NovoLog) - Injection
- 8.7 Insulin Detemir (Levemir FlexTouch) - Injection
- 8.8 Insulin Glargine (Lantus) - Injection
- 8.9 Insulin Aspart/Insulin Protamine Aspart (NovoLog) - Injection

9. US BIOSIMILAR MARKET: GLARGINE BASAGLAR – THE FIRST “BIOSIMILAR” INSULIN

- 9.1 Overview
- 9.2 Impact of Biosimilar Insulin

10. US ANTIDIABETICS DRUG MARKET DYNAMICS

- 10.1 Accelerative Parameters
- 10.2 Major Challenges

11. US ANTIDIABETICS DRUG MARKET FUTURE PROSPECTS

12. COMPETITIVE LANDSCAPE

- 12.1 AstraZeneca
- 12.2 Bayer
- 12.3 Boehringer Ingelheim
- 12.4 Eli-Lilly
- 12.5 Johnson & Johnson

12.6 Merck

12.7 Novartis

12.8 Novo Nordisk

12.9 Sanofi

12.10 Takeda

List Of Figures

LIST OF FIGURES

- Figure 1-1: Illustration of the Categories of Diabetes Mellitus
- Figure 1-2: Percentage of Different types of Antidiabetics Used
- Figure 2-1: Historical Pathway of oral Diabetic Medication
- Figure 3-1: Control of Glucose Uptake during Muscle Working
- Figure 4-1: Categorization of Oral Antidiabetics Approved in US
- Figure 4-2: Chemical Structure of Metformin, Phenformin & Buformin
- Figure 4-3: Illustration of the Sub-Categories of Sulfonylureas
- Figure 5-1: Mechanism of Insulin in Regulation of Blood Glucose Levels
- Figure 5-2: Differences between Diabetes Mellitus 1 & 2 over Insulin
- Figure 5-3: Structure of Differentiation of Peptidic Insulin Analogs
- Figure 5-4: Demonstration of Action Profiles of Insulin Analogue
- Figure 5-5: Activity Profiles of Different Types of Insulin
- Figure 5-6: Difference between Lantus & Levemir
- Figure 6-1: US: Number of Type 1 Diabetes Incidence (Million), 2016 & 2022
- Figure 6-2: US: Number of Type 2 Diabetes Incidence (Million), 2014 - 2022
- Figure 6-3: US: Type 1 Diabetes Prevalence Rate (%), 2016 & 2022
- Figure 6-4: US: Type 2 Diabetes Prevalence Rate (%), 2014 - 2022
- Figure 6-5: US: Diabetes Prevalence Rate among Adults Aged 18+ (%), 2010 - 2016
- Figure 6-6: US: Obesity Rate Among Adults Aged 18+ (%), 2010 - 2016
- Figure 6-7: US: Percentage of Adults with Obesity by State (%), 2015
- Figure 6-8: Illustration of Total Cost of Diabetes Expenditure
- Figure 6-9: Annual Average Cost Of Diabetes per Person in US
- Figure 6-10: US: Productivity Loss Due To Type 1 Diabetes (US\$ Billion), 2014 - 2022
- Figure 6-11: US: Productivity Loss Due To Type 2 Diabetes (US\$ Billion), 2014 - 2022
- Figure 6-12: US: Medical Cost for Type 1 Diabetes (US\$ Billion), 2014-2022
- Figure 6-13: US: Medical Cost for Type 2 Diabetes (US\$ Billion), 2014-2022
- Figure 7-1: Overview of Diabetic Drug Market Segmentation
- Figure 7-2: US: Antidiabetics Drug Market (US\$ Billion), 2014 - 2022
- Figure 7-3: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US\$ Billion), 2016
- Figure 7-4: US - Percentage of Most Common Class of Antidiabetics Drugs
- Figure 7-5: US – Percentage of Generally Prescribed Anti-Diabetic Drugs (%)
- Figure 8-1: US - Insulin Degludec (Tresiba) Injection Sales (US\$ Million), 2016-2022
- Figure 8-2: US -Insulin Lispro Injection Sales (US\$ Million), 2016-2022
- Figure 8-3: US - Insulin Glargine (Toujeo) Injection Sales (US\$ Million), 2016-2022

Figure 8-4: US - Insulin Glulisine (Apidra) Injection Sales (US\$ Million), 2016-2022

Figure 8-5: US - Insulin Detemir (Levemir FlexTouch) Injection Sales (US\$ Million), 2016-2022

Figure 9-1: Major Accelerative Parameters for Antidiabetic Market in US

Figure 9-2: Estimated Impact of Increasing Trend in Obesity by 2020

Figure 9-3: Estimated Increase in Total Number with Diagnosed Diabetes till 2050

Figure 9-4: Major challenges in Antidiabetics Market

Figure 9-5: Important Challenges with the Use of Insulin

Figure 10-1: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US\$ Billion), 2022

Figure 10-2: Illustration of Antidiabetic Drugs Under Development

I would like to order

Product name: US Antidiabetics Drug Market Outlook 2022

Product link: <https://marketpublishers.com/r/U0B1E440CAFEN.html>

Price: US\$ 1,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U0B1E440CAFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970